Lp-PLA2, a new biomarker of vascular disorders in metabolic diseases
Liliana Mannucci
International Journal of Immunopathology and Pharmacology, 2019
View PDFchevron_right
Lipoprotein-Associated Phospholipase A2 Activity Predicts Cardiovascular Events in High Risk Coronary Artery Disease Patients
Luigi Pedon
PLOS ONE, 2012
View PDFchevron_right
Elevated Lp-PLA2 Levels Add Prognostic Information to the Metabolic Syndrome on Incidence of Cardiovascular Events Among Middle-Aged Nondiabetic Subjects
Margaretha Persson
Arteriosclerosis, Thrombosis, and Vascular Biology, 2007
View PDFchevron_right
Lipoprotein-Associated Phospholipase A2: A Promising Vascular-Specific Marker for Screening Cardiovascular Risk?
Dr. Marguerite M Engler
Progress in Cardiovascular Nursing, 2000
View PDFchevron_right
High Plasma Phospholipase A2 Activity, Inflammation Markers, and LDL Alterations in Obesity With or Without Type 2 Diabetes
Flor Lopez
Obesity, 2010
View PDFchevron_right
Unexpected inverse relationship between impaired glucose metabolism and lipoprotein-associated phospholipase A2 activity in patients with stable vascular disease
Otto Mayer, Peter Wohlfahrt
European Journal of Internal Medicine, 2014
View PDFchevron_right
Lp-PLA2—A novel marker of atherosclerosis: To treat or not to treat?
Dimitris Tousoulis, Nikolaos Papageorgiou
International Journal of Cardiology, 2013
View PDFchevron_right
Lipoprotein-Associated Phospholipase A 2 Activity Predicts Progression of Subclinical Coronary Atherosclerosis
Gregory Kinney
Diabetes Technology & Therapeutics, 2011
View PDFchevron_right
Lipoprotein-associated phospholipase A2 activity improves risk discrimination of incident coronary heart disease among women
Estevo Santamarina
American Heart Journal, 2011
View PDFchevron_right
The role of lipoprotein-associated phospholipase A2 on cardiovascular disease risk assessment and plaque rupture: a clinical review
Richard Batsell
Journal of Clinical Lipidology, 2009
View PDFchevron_right
Lipoprotein-associated phospholipase A2: Pathogenic mechanisms and clinical utility for predicting cardiovascular events
Sanja Stankovic
Current Atherosclerosis Reports, 2006
View PDFchevron_right
The Correlation between Lipoprotein-Associated Phospholipase A2 and Atherosclerosis (ox-LDL) in Centrally Obese Men
Dian Ari
The Indonesian Biomedical Journal, 2012
View PDFchevron_right
On the present and future role of Lp-PLA2 in atherosclerosis-related cardiovascular risk prediction and management
Zlatko FRAS
Archives of Medical Science
View PDFchevron_right
Systematic Review of the Association between Lipoprotein � Associated Phospholipase A2 and Atherosclerosis
Dong Zhao
American Chinese Journal of Medicine and Science, 2011
View PDFchevron_right
An evolving story of lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular risk prediction
Colin Macphee
European Heart Journal, 2004
View PDFchevron_right
Lipoprotein-Associated Phospholipase A2 Mass and Activity and Risk of Cardiovascular Disease in a Population With High Prevalences of Obesity and Diabetes: The Strong Heart Study
Y. Pokharel, Arthur Roberts
Diabetes Care, 2012
View PDFchevron_right
Clinical Utility of Lipoprotein-Associated Phospholipase A2 for Cardiovascular Disease Prediction in a Multiethnic Cohort of Women
Nancy Cook
Clinical Chemistry, 2012
View PDFchevron_right
Lipoprotein-Associated Phospholipase A2 Is an Independent Marker for Coronary Endothelial Dysfunction in Humans
Eric Yang
2010
View PDFchevron_right
Lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ) and risk of cardiovascular disease in older adults: Results from the Cardiovascular Health Study
Cam Solomon
View PDFchevron_right
Τhe role of lipoprotein-associated phospholipase A2 in atherosclerosis
Κωνσταντίνος Τέλλης
View PDFchevron_right
Lipoprotein-associated phospholipase A2, inflammatory biomarkers, and risk of cardiovascular disease in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)
Peter Macfarlane
Atherosclerosis, 2010
View PDFchevron_right
Comparison of Lipoprotein-Associated Phospholipase A2 and High Sensitive C-Reactive Protein as Determinants of Metabolic Syndrome in Subjects without Coronary Heart Disease: In Search of the Best Predictor
Carlos Navarrete
International Journal of Endocrinology, 2015
View PDFchevron_right
Diabetes status modifies the long-term effect of lipoprotein-associated phospholipase A2 on major coronary events
Gwen Kennedy
Diabetologia, 2021
View PDFchevron_right
Pathophysiological Role and Clinical Significance of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Bound to LDL and HDL
Κωνσταντίνος Τέλλης
View PDFchevron_right
Role of Lipoprotein-Associated Phospholipase A 2 in Atherosclerosis
santhi silambanan
Arteriosclerosis, Thrombosis, and Vascular Biology, 2005
View PDFchevron_right